Association of Patient, Prescriber, and Region With the Initiation of First Prescription of Biologic Disease-Modifying Antirheumatic Drug Among Older Patients With Rheumatoid Arthritis and Identical Health Insurance Coverage

IMPORTANCE: Prescribing the first biologic treatment for rheumatoid arthritis (RA) is an important decision for patients, their physicians, and payers, with considerable costs and clinical implications. Conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) have known effectiveness...

Descripción completa

Detalles Bibliográficos
Autores principales: Tatangelo, Mark, Tomlinson, George, Paterson, J. Michael, Ahluwalia, Vandana, Kopp, Alex, Gomes, Tara, Bansback, Nick, Bombardier, Claire
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2019
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6902765/
https://www.ncbi.nlm.nih.gov/pubmed/31808927
http://dx.doi.org/10.1001/jamanetworkopen.2019.17053

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6902765/
https://www.ncbi.nlm.nih.gov/pubmed/31808927
http://dx.doi.org/10.1001/jamanetworkopen.2019.17053

Ejemplares similares